Official Title

BOTOX® (Onabotulinumtoxin A) Injection(s) as a Treatment for Carpal Tunnel Syndrome
  • Phase

    Phase 2
  • Study Type

    Interventional
  • Study Participants

    10
This study will be a prospective double blind controlled randomized trial of ten patients diagnosed with Carpal Tunnel Syndrome (CTS). The study will be completed at offices of medical practices in Arizona. Patients who meet inclusion criteria will be randomly distributed into two groups: a BOTOX® (onabotulinumtoxin A) injection group and a Normal Saline Injection (NS) (Placebo group). Each group will consist of five randomly assigned individuals.
This is a pilot study, to assist with determining appropriate BOTOX® (onabotulinumtoxin A) dosing and injection locations in patients suffering from CTS.

Outcome measures will be obtained at follow-up at 6, 12, and 18 weeks post BOTOX® (onabotulinumtoxin A) injection and post saline injection using the same scales and instruments at baseline, namely Levine scale, JAMAR pinch dynamometer, EDX/NCS and NMUS. These measurements will be used to identify the effectiveness of BOTOX® (onabotulinumtoxin A) in decreasing thenar muscle strength, appropriate BOTOX® (onabotulinumtoxin A) injection dosing, and ability to decrease the inflammation, median nerve dysfunction, edema, symptoms of pain, numbness, and tingling often with associated with CTS.
Study Started
Oct 31
2014
Primary Completion
Feb 29
2016
Study Completion
Feb 29
2016
Results Posted
Sep 27
2017
Last Update
Sep 27
2017

Drug Botulinum Toxin Type A

40 units of BOTOX® (onabotulinumtoxin A) divided into two injection sites of 20 units each

  • Other names: Botox

Drug Placebo

Placebo (Normal Saline) divided into 2 injections of .4cc each

  • Other names: Normal Saline

Botulinum Toxin Type A Active Comparator

After appropriate consent, each patient will receive 40 units of BOTOX® (onabotulinumtoxin A) divided into two injection sites of 20 units each into Opponens Pollicis (OP) and the Abductor Pollicis Brevis (APB)

Placebo Placebo Comparator

.4cc/muscle of Normal saline will be injected into two injection sites each into Opponens Pollicis (OP) and the Abductor Pollicis Brevis (APB)

Criteria

Inclusion Criteria:

Patient history: evaluated using the Levine Scale for CTS, a self-administered questionnaire which assesses the function and severity of CTS.
Physical Exam: including use of JAMAR pinch dynamometer to quantify initial baseline strength and confirm decreased pinch strength post injection to verify effective BOTOX® (onabotulinumtoxin A) injection.
Electrodiagnostics (EDX): The following criteria would establish CTS through EDX namely baseline electromyogram (EMG) and nerve conduction studies (NCS): a) median nerve distal motor latency (DML) >4.3ms or >0.9ms above the ulnar nerve DML b) median distal sensory latency (DSL) to D-1 >2.9ms or >0.4ms above radial nerve D-1 DSL. c) median D-2 DSL >3.7ms or >0.4ms above ulnar nerve D-5 DSL (5). d) median mixed nerve palm-to-wrist latency (at 8cm) >2.2ms or >.3ms above ulnar mixed nerve palm-to-wrist latency (at 8cm).
Imaging & Measurements (NMUS): Carpal tunnel images will be obtained in a transverse plane in both a neutral relaxed position at the level of the pisiform and longitudinally during neutral and Dynamic Stress Testing (DST) by a A Sonosite M-Turbo 6-13 MHz ultrasound system or another similar system (+ 2% accuracy). Measurements: Transverse images of the CT will measure the median nerve cross sectional area (CSA) at the level of the pisiform bone. CSA measurements greater than 11 mm2 are indicative of CTS. Borderline CSA measurements would require wrist forearm ratio (WFR) measurements to be a WFR > 1.5. Patients will need to have a CSA >11mm2, (or WFR >1.5) and show median nerve compression during DST of at least 30% to be included.

Exclusion Criteria:

Patients with prior carpal tunnel surgery, prior history of BOTOX® (onabotulinumtoxin A) injection
Steroid injection two months prior or three months after BOTOX® (onabotulinumtoxin A) CTS injection, median nerve denervation on needle EMG
Major limb trauma or surgery, dysphagia
Neuromuscular junction disorder (ie: Myasthenia gravis or Lambert-Eaton syndrome)
Currently pregnant or breast feeding
Patients with severe CTS identified by Levine scale >4, electrodiagnostics, and/or unable to meet the inclusion criteria as identified above would be excluded as participants in this study.

Summary

Botulinum Toxin Type A

Placebo

All Events

Event Type Organ System Event Term Botulinum Toxin Type A Placebo

Change From Baseline Levine Symptom Severity Scale Status at Weeks 6, 12,18.

Patients with Levine score < 4 were included in the study. The score for this assessment can range from 11-55.

Botulinum Toxin Type A

Visit 2-Week 6

0.4
Scores on a scale (Mean)
Standard Deviation: 6.8

Visit 3-Week 12

-4.2
Scores on a scale (Mean)
Standard Deviation: 5.1

Visit 4-Week 18

-5.4
Scores on a scale (Mean)
Standard Deviation: 8.7

Placebo

Visit 2-Week 6

-3.2
Scores on a scale (Mean)
Standard Deviation: 6.8

Visit 3-Week 12

-9.4
Scores on a scale (Mean)
Standard Deviation: 8.3

Visit 4-Week 18

-6.8
Scores on a scale (Mean)
Standard Deviation: 6.8

Change From Baseline Levine Function Severity Scale Status at Weeks 6, 12,18.

Patients with Levine score of < 4 were included in the study. The score for this assessment can range from 8-40

Botulinum Toxin Type A

Visit 2-Week 6

-1.0
Scores on a scale (Mean)
Standard Deviation: 9.3

Visit 3-Week 12

-3.8
Scores on a scale (Mean)
Standard Deviation: 4.8

Visit 4-Week 18

-4.0
Scores on a scale (Mean)
Standard Deviation: 8.6

Placebo

Visit 2-Week 6

-4.4
Scores on a scale (Mean)
Standard Deviation: 11.9

Visit 3-Week 12

-9.6
Scores on a scale (Mean)
Standard Deviation: 9.3

Visit 4-Week 18

-12.8
Scores on a scale (Mean)
Standard Deviation: 6.1

Change From Baseline in Median Nerve Compression on Neuromuscular Ultrasound at Week 6, Week 12, and Week 18.

Neuromuscular ultrasound measures nerve compression (swelling) by cross sectional area of median nerve, in format % change from baseline.

Botulinum Toxin Type A

Visit 2-Week 6

-13.0
% change (Mean)
Standard Deviation: 15.3

Visit 3-Week 12

-15.9
% change (Mean)
Standard Deviation: 19.5

Visit 4-Week 18

-12.2
% change (Mean)
Standard Deviation: 17.8

Placebo

Visit 2-Week 6

-20.2
% change (Mean)
Standard Deviation: 18.8

Visit 3-Week 12

-13.3
% change (Mean)
Standard Deviation: 9.4

Visit 4-Week 18

-4.7
% change (Mean)
Standard Deviation: 14.0

Change From Baseline Electrodiagnostics Distal Sensory Median Nerve Latency at Week 6, Week 12, and Week 18.

Latency is the interval between the stimulation of a muscle and the observed response, measuring conduction speed in milliseconds compared to baseline

Botulinum Toxin Type A

Visit 2-Week 6

-0.1
milliseconds (Mean)
Standard Deviation: 0.4

Visit 3-Week 12

-0.3
milliseconds (Mean)
Standard Deviation: 0.3

Visit 4-Week 18

-0.3
milliseconds (Mean)
Standard Deviation: 0.3

Placebo

Visit 2-Week 6

-0.1
milliseconds (Mean)
Standard Deviation: 0.1

Visit 3-Week 12

Visit 4-Week 18

-0.1
milliseconds (Mean)
Standard Deviation: 0.3

Change From Baseline Electrodiagnostics Motor Median Nerve Latency at Week 6, Week 12, and Week 18.

Latency is the interval between the stimulation of a muscle and the observed response measuring nerve conduction speed in milliseconds.

Botulinum Toxin Type A

Visit 2-Week 6

-0.2
milliseconds (Mean)
Standard Deviation: 0.3

Visit 3-Week 12

-0.4
milliseconds (Mean)
Standard Deviation: 0.5

Visit 4-Week 18

-0.6
milliseconds (Mean)
Standard Deviation: 0.5

Placebo

Visit 2-Week 6

-0.1
milliseconds (Mean)
Standard Deviation: 0.1

Visit 3-Week 12

-0.1
milliseconds (Mean)
Standard Deviation: 0.2

Visit 4-Week 18

-0.1
milliseconds (Mean)
Standard Deviation: 0.3

Change From Baseline Jamar Pinch (Unrelated Dominant Hand - Mean Value of All Repetitions/Positions) at Weeks 6, 12,18.

Mean value of one finger and two finger opposition pinch between 1st and 5th and 1st with 4th and 5th phalanges.

Botulinum Toxin Type A

Visit 2-Week 6

1.1
Pounds of Force (LBF) (Mean)
Standard Deviation: 1.2

Visit 3-Week 12

1.4
Pounds of Force (LBF) (Mean)
Standard Deviation: 0.5

Visit 4-Week 18

1.4
Pounds of Force (LBF) (Mean)
Standard Deviation: 0.5

Placebo

Visit 2-Week 6

0.5
Pounds of Force (LBF) (Mean)
Standard Deviation: 1.2

Visit 3-Week 12

-0.1
Pounds of Force (LBF) (Mean)
Standard Deviation: 1.7

Visit 4-Week 18

0.4
Pounds of Force (LBF) (Mean)
Standard Deviation: 1.2

Total

10
Participants

Age, Continuous

56.35
years (Mean)
Standard Deviation: 5.7

Age, Categorical

Region of Enrollment

Sex: Female, Male

Overall Study

Botulinum Toxin Type A

Placebo